BEYOND D2: EFFICACY AND SAFETY OF XANOMELINE/TROSPIUM CHLORIDE IN SCHIZOPHRENIA (WPA-WCP 2026) - Oct 15, 2026 - Abstract #SO100; Pres time: Sep 24, 2026; 12:25 PM - 12:30 PM; Location: Station 05; "Xanomeline/trospium effectively improves positive and negative symptoms in schizophrenia, with cognitive benefits in patients with baseline deficits. Its novel M1/M4 receptor mechanism is associated with a favourable safety profile, highlighting its potential as an alternative to conventional antipsychotics."
Clinical • CNS Disorders • Psychiatry • Schizophrenia
|